Autres langues Axsome Therapeutics, Inc. Boerse Muenchen

Actions

19X

US05464T1043

Produits pharmaceutiques

Marché Fermé - Boerse Muenchen 22:43:56 02/10/2026			Varia. 5j.	Varia. 1 janv.
158,15 ^EUR	-1,77%		-6,31%	+25,15%

29/09	Axsome Therapeutics, Inc. : Deutsche Bank Securities favorable sur le dossier	ZM
25/09	Auvelity d'Axsome poursuit sa bonne dynamique de lancement, selon Mizuho	MT

Autres langues

25/09	Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says
21/09	Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer?S Disease Agitation Presented At Psych Congress 2026
21/09	Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
21/09	Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
18/09	Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says
17/09	Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
17/09	Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
04/09	Axsome Therapeutics Insider Sold Shares Worth $2,086,500, According to a Recent SEC Filing
02/09	Axsome Therapeutics to Participate in Upcoming Investor Conferences
01/09	Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says
31/08	Axsome Therapeutics Initiates SUMMIT Phase 3 Trial Of AXS-05 In Smoking Cessation
31/08	Axsome Therapeutics Starts Phase 3 Trial of AXS-05 for Smoking Cessation
31/08	Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
11/08	Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says
10/08	Axsome Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Stocks Mostly Up Pre-Bell as Traders Assess Middle East Developments, Await Key Inflation Data
10/08	Axsome Therapeutics Q2 Loss Widens, Revenue Increases
10/08	Earnings Flash (AXSM) Axsome Therapeutics Posts Q2 Loss $0.99 a Share, vs. FactSet Est of $0.89 Loss
10/08	Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q2 Revenue $218.4M, vs. FactSet Est of $221.1M
10/08	Axsome: Q2 Earnings Snapshot
10/08	Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
15/07	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
15/07	Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
15/07	Axsome's New Drug Application for Narcolepsy Treatment Accepted by FDA
15/07	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy